Xiao Chang, Su Zu-lan, Wu Qiu-liang, Gao Hong-yi, Fang Jian-chen, Xia Zhong-jun, Guan Zhong-zhen
The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Zhonghua Bing Li Xue Za Zhi. 2005 Jan;34(1):22-7.
To investigate the clinical and pathological features of non-Hodgkin's lymphoma (NHL) and to evaluate the applicability of the new WHO classification of lymphoid neoplasms.
According to the new WHO classification, a total of 500 cases of non-Hodgkin's lymphoma diagnosed during the period 1992 - 2003 were reviewed and reappraised with their morphological, immunological and clinical characteristics. Clinical survival analysis was performed in 156 cases that accompanied with follow-up data.
Among 500 cases previously diagnosed as lymphomas, 493 cases (98.6%) were confirmed to be NHL, of which B-cell neoplasms was 69.0% and T/NK-cell neoplasms 29.8%. Overall, 6 subtypes including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), unspecified peripheral T-cell lymphoma (PT-un), precursor T-lymphoblastic lymphoma (T-LBL), extranodal marginal zone B-cell lymphoma of MALT type (MALT) and B-small lymphocytic lymphoma (B-SLL) were among the most common subtypes. In pediatric and young patient populations, the most common subtypes were LBL, DLBCL and Burkitt's lymphoma. The frequency of LBL in all patients, especially in the juniors, was much higher than those reported outside Mainland China, and the frequency of FL was much higher than the reported in Mainland China. The frequency of FL was much higher than the reported in Mainland China. Clinical survivals among different histological subtypes of NHL varied considerably with statistic significance (P < 0.001). Marginal zone B-cell lymphoma and SLL demonstrated the best prognosis, LBL and PT-un both the worst, whereas DLBCL and FL had an intermediate prognosis, however, subgrouping of FL according to WHO classification did not reveal a significant survival difference (P > 0.05).
Basing upon the results of a comprehensive survey on the morphologic features, immunophenotyping and clinical data of the above cases, the new WHO classification of lymphoid neoplasms is practical and easily applicable for routine pathological evaluation of lymphoproliferaive disorders and in guiding the clinical management. It appears that the diagnostic and grading criteria for FL in Mainland China need to be re-evaluated.
探讨非霍奇金淋巴瘤(NHL)的临床和病理特征,并评估世界卫生组织(WHO)淋巴肿瘤新分类的适用性。
根据WHO新分类,回顾并重新评估了1992年至2003年期间诊断的500例非霍奇金淋巴瘤病例的形态学、免疫学和临床特征。对156例有随访数据的病例进行了临床生存分析。
在先前诊断为淋巴瘤的500例病例中,493例(98.6%)确诊为NHL,其中B细胞肿瘤占69.0%,T/NK细胞肿瘤占29.8%。总体而言,弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤(FL)、未特指的外周T细胞淋巴瘤(PT-un)、前体T淋巴细胞淋巴瘤(T-LBL)、黏膜相关淋巴组织边缘区B细胞淋巴瘤(MALT)和B小淋巴细胞淋巴瘤(B-SLL)这6种亚型是最常见的亚型。在儿童和年轻患者群体中,最常见的亚型是LBL、DLBCL和伯基特淋巴瘤。LBL在所有患者中,尤其是青少年中的发生率远高于中国大陆以外地区报道的发生率,而FL的发生率远高于中国大陆报道的发生率。NHL不同组织学亚型的临床生存率差异显著(P < 0.001)。边缘区B细胞淋巴瘤和SLL预后最佳,LBL和PT-un预后最差,而DLBCL和FL预后中等,然而,根据WHO分类对FL进行亚组分析未显示出显著的生存差异(P > 0.05)。
基于上述病例的形态学特征、免疫表型和临床数据的综合研究结果,WHO淋巴肿瘤新分类对于淋巴增殖性疾病的常规病理评估和指导临床治疗具有实用性且易于应用。中国大陆FL的诊断和分级标准似乎需要重新评估。